Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Ribociclib and cornea verticillata: a case report

Poster Details

First Author: E. Espejo de los Riscos SPAIN

Co Author(s):    M. Rodriguez Calvo de Mora   C. Alba Linero                 

Abstract Details


To report a new ethiology of Cornea Verticillata (Vortex Keratopathy) in relation with Ribociclib, a new drug with potential antineoplastic activity


Tertiary Care Center, Ophthalmology Service, Cataract and Primary Eye Care Unit


A case of a woman with breast cancer that has been treated with Ribociclib. She notices haloes with no decreased of vision in both eyes. In the biomicroscopy only appeared golden brown deposits in the inferior interpalpebal portion of the cornea in a clockwise fashion. The funduscopy didn’t show anything of interest.


Cornea Verticillate or Vortex Keratopathy is characterized by whorl-like corneal epithelial deposits. There is a comprehensive list of systemic drugs (Amiodarona, Chloroquine…) is associated with it, and the differential diagnosis should also include Fabry’s disease. In our findings, there is no evidence in the relation between Ribociclib with Cornea Verticillata.


Ribociclib is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. Actually, this agent is in Phase III study to treat hormone receptor-positive in certain types of cancer. We report a side effect of this new drug to include in the list of etiology of Cornea Verticillata.

Financial Disclosure:


Back to Poster listing